JP2023134488A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023134488A5 JP2023134488A5 JP2023101803A JP2023101803A JP2023134488A5 JP 2023134488 A5 JP2023134488 A5 JP 2023134488A5 JP 2023101803 A JP2023101803 A JP 2023101803A JP 2023101803 A JP2023101803 A JP 2023101803A JP 2023134488 A5 JP2023134488 A5 JP 2023134488A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- modified
- molecule according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 30
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 241000710929 Alphavirus Species 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 11
- 101800001603 Capsid protein C Proteins 0.000 claims 5
- 101800001847 Core protein precursor Proteins 0.000 claims 5
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 3
- 108010087302 Viral Structural Proteins Proteins 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 2
- 101800001643 6K protein Proteins 0.000 claims 1
- 101710201734 E3 protein Proteins 0.000 claims 1
- 101710125507 Integrase/recombinase Proteins 0.000 claims 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims 1
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 1
- 241000710924 Togaviridae Species 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409228P | 2016-10-17 | 2016-10-17 | |
| US62/409,228 | 2016-10-17 | ||
| PCT/US2017/054928 WO2018075235A1 (en) | 2016-10-17 | 2017-10-03 | Recombinant virus replicon systems and uses thereof |
| JP2019520535A JP7382230B2 (ja) | 2016-10-17 | 2017-10-03 | 組み換えウイルスレプリコン系及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520535A Division JP7382230B2 (ja) | 2016-10-17 | 2017-10-03 | 組み換えウイルスレプリコン系及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023134488A JP2023134488A (ja) | 2023-09-27 |
| JP2023134488A5 true JP2023134488A5 (enExample) | 2024-03-07 |
Family
ID=60153459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520535A Active JP7382230B2 (ja) | 2016-10-17 | 2017-10-03 | 組み換えウイルスレプリコン系及びその使用 |
| JP2023101803A Withdrawn JP2023134488A (ja) | 2016-10-17 | 2023-06-21 | 組み換えウイルスレプリコン系及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520535A Active JP7382230B2 (ja) | 2016-10-17 | 2017-10-03 | 組み換えウイルスレプリコン系及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11364310B2 (enExample) |
| EP (1) | EP3526332B1 (enExample) |
| JP (2) | JP7382230B2 (enExample) |
| KR (1) | KR102718353B1 (enExample) |
| CN (1) | CN110073002B (enExample) |
| AU (1) | AU2017347725B2 (enExample) |
| BR (1) | BR112019007433A2 (enExample) |
| ES (1) | ES2993107T3 (enExample) |
| MX (1) | MX2019004499A (enExample) |
| WO (1) | WO2018075235A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017180770A1 (en) | 2016-04-13 | 2017-10-19 | Synthetic Genomics, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| WO2018075235A1 (en) * | 2016-10-17 | 2018-04-26 | Synthetic Genomics, Inc. | Recombinant virus replicon systems and uses thereof |
| US11845939B2 (en) | 2016-12-05 | 2023-12-19 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
| JP7494117B2 (ja) | 2018-01-19 | 2024-06-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えレプリコン系を使用する免疫応答の誘導および増強 |
| KR20200144093A (ko) | 2018-02-17 | 2020-12-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 막 단백질 전달을 위한 조성물 및 방법 |
| JP2022512625A (ja) * | 2018-10-08 | 2022-02-07 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 生物学的製剤の投与のためのアルファウイルスベースのレプリコン |
| US12496274B2 (en) | 2018-11-14 | 2025-12-16 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for compartment-specific cargo delivery |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3986458A1 (en) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| IL293051A (en) | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
| CN116134131A (zh) | 2019-12-31 | 2023-05-16 | 伊利克斯根治疗公司 | 核酸和蛋白质向细胞和组织的基于温度的瞬时递送 |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| WO2021183564A1 (en) | 2020-03-09 | 2021-09-16 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| KR20210116324A (ko) | 2020-03-12 | 2021-09-27 | 기초과학연구원 | 게놈 서열 변이를 가지는 세포 사멸 유도용 조성물 및 상기 조성물을 이용한 세포 사멸 유도 방법 |
| CA3172489A1 (en) | 2020-03-23 | 2021-09-30 | Amit KHANDHAR | Nanoemulsion compositions and methods for delivery of nra |
| JP2023521194A (ja) | 2020-04-13 | 2023-05-23 | ヤンセン バイオテツク，インコーポレーテツド | Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用 |
| CA3183500A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| KR20230009489A (ko) | 2020-05-11 | 2023-01-17 | 얀센 파마슈티칼즈, 인코포레이티드 | 안정화된 코로나 바이러스 스파이크 단백질을 암호화하는 rna 레플리콘 |
| WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175721A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CA3188801A1 (en) | 2020-07-08 | 2022-01-13 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
| AU2021315795A1 (en) * | 2020-07-31 | 2023-02-23 | Replicate Bioscience, Inc. | Modified Chikungunya viruses and Sindbis viruses and uses thereof |
| JP2023537609A (ja) | 2020-08-14 | 2023-09-04 | アークトゥラス・セラピューティクス・インコーポレイテッド | 脂質ナノ粒子を凍結乾燥する方法 |
| CN112458064A (zh) * | 2020-11-20 | 2021-03-09 | 广西大学 | 盖他病毒全长感染性克隆、复制子系统及其制备和应用 |
| WO2022133230A1 (en) | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| CN112852841A (zh) * | 2021-02-03 | 2021-05-28 | 郑州大学 | 一种高效表达目的蛋白的顺式复制子rna构建体 |
| US20240327865A1 (en) * | 2021-07-09 | 2024-10-03 | Replicate Bioscience, Inc. | Modified eastern equine encephalitis viruses, self-replicating rna constructs, and uses thereof |
| CA3232658A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Rna vaccines against infectious diseases |
| EP4404957A4 (en) | 2021-09-22 | 2025-08-06 | Hdt Bio Corp | CANCER THERAPY COMPOSITIONS AND THEIR USES |
| WO2023048759A1 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Sars-cov-2 rna vaccine compositions and methods of use |
| EP4404919A4 (en) | 2021-09-22 | 2025-08-20 | Hdt Bio Corp | DRIED NANOPARTICLE COMPOSITIONS |
| KR20250010642A (ko) | 2022-05-12 | 2025-01-21 | 엠에스디 인터내셔널 비즈니스 게엠베하 | 안정화된 융합-전 hmpv 융합 단백질 |
| CN119563031A (zh) * | 2022-07-08 | 2025-03-04 | 嘉晨西海(杭州)生物技术有限公司 | 经修饰的自复制mRNA |
| WO2025088152A1 (en) | 2023-10-27 | 2025-05-01 | Ziphius Nv | MODIFIED 5'UTRs |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| US4738927A (en) | 1982-03-31 | 1988-04-19 | Ajinomoto Co. Inc. | Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell |
| US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4892743A (en) | 1983-12-21 | 1990-01-09 | Schering Corporation | Novel hybrid interferon species |
| WO1985002862A1 (en) | 1983-12-23 | 1985-07-04 | Monash University | PRODUCTION OF HUMAN INTERFERON-alpha |
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| JPH04503301A (ja) | 1988-12-01 | 1992-06-18 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ノース カロライナ | 合成インターロイキン―６ |
| US5225337A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| US5246921A (en) | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
| US5780036A (en) | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| CA2168583C (en) | 1993-08-02 | 2007-10-02 | Francis V. Chisari | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus |
| SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
| DE19712889A1 (de) | 1997-03-27 | 1998-10-01 | Bosch Gmbh Robert | Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe |
| CN1198665C (zh) | 1997-04-03 | 2005-04-27 | 依莱克脱罗弗克脱联合股份有限公司 | 将药物和核酸导入骨骼肌的方法 |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| US5873849A (en) | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| US6117660A (en) | 1997-06-10 | 2000-09-12 | Cytopulse Sciences, Inc. | Method and apparatus for treating materials with electrical fields having varying orientations |
| JP2002507985A (ja) | 1997-06-30 | 2002-03-12 | ローヌ−プーラン・ロレ・エス・アー | 横紋筋に核酸を導入する改良法およびその組合せ |
| US5958060A (en) | 1998-01-02 | 1999-09-28 | General Electric Company | Method and apparatus for clock control and synchronization |
| CA2337652C (en) | 1998-07-13 | 2013-03-26 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
| US20040213805A1 (en) | 1999-10-12 | 2004-10-28 | Verheije Monique Helene | Deletions in arterivirus replicons |
| AU2001290642A1 (en) | 2000-09-07 | 2002-03-22 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
| US6538922B1 (en) | 2000-09-27 | 2003-03-25 | Sandisk Corporation | Writable tracking cells |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| AU2002242016A1 (en) | 2001-02-01 | 2002-08-12 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
| EP1278382B1 (en) | 2001-07-19 | 2007-02-14 | Telefonaktiebolaget LM Ericsson (publ) | Method and apparatus for solving number portability in origin |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| AU2003297860A1 (en) | 2002-12-12 | 2004-07-09 | The Board Of Regents Of The University Of Texas System | Large scale production of packaged alphavirus replicons |
| US7419674B2 (en) | 2003-07-11 | 2008-09-02 | Alpha Vax, Inc. | Alpha virus-based cytomegalovirus vaccines |
| US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| US20050070700A1 (en) | 2003-09-30 | 2005-03-31 | Matthias Giese | Equine arteritis virus vaccine |
| JP5221127B2 (ja) | 2004-03-08 | 2013-06-26 | アイコアー メディカル システムズ、インク． | 電気を利用した治療剤移送のための改良された装置 |
| US8859198B2 (en) | 2006-06-06 | 2014-10-14 | Abl Sa | Detection and use of antiviral resistance mutations |
| WO2008115199A2 (en) * | 2006-08-18 | 2008-09-25 | The University Of North Carolina At Chapel Hill | Chimeric virus vaccines |
| EP3524316B1 (en) | 2006-10-17 | 2024-08-07 | Inovio Pharmaceuticals, Inc. | Electroporation devices for electroporation of cells in mammals |
| WO2008073303A2 (en) | 2006-12-07 | 2008-06-19 | Switchgear Genomics | Transcriptional regulatory elements of biological pathways, tools, and methods |
| KR100836745B1 (ko) | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| JP5602624B2 (ja) * | 2007-06-21 | 2014-10-08 | アルファバックス， インコーポレイテッド | αウイルス構造タンパク質の発現のためのプロモーターレスカセット |
| WO2009056535A2 (en) | 2007-10-29 | 2009-05-07 | Genimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
| BR112012002628B1 (pt) | 2009-08-07 | 2021-09-08 | Transgene Sa | Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes |
| DK2519266T3 (da) | 2009-12-31 | 2017-11-06 | Medigen Inc | Infektiøse DNA vacciner mod Chikungunya virus |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| DK2655621T3 (en) | 2010-12-20 | 2018-08-13 | Massachusetts Gen Hospital | Polycomb-associated non-coding RNAS |
| WO2012109668A1 (en) | 2011-02-11 | 2012-08-16 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same |
| EP3797824B1 (en) | 2011-06-28 | 2024-06-12 | Inovio Pharmaceuticals, Inc. | A miniminally invasive dermal electroporation device |
| TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| US8961995B2 (en) * | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| US9956343B2 (en) | 2012-12-13 | 2018-05-01 | Panasonic Healthcare Holdings Co., Ltd. | Pharmaceutical injection device |
| WO2014170493A2 (en) * | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
| WO2015024669A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Combination vaccine |
| WO2016020538A1 (en) | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
| KR102586707B1 (ko) | 2014-10-01 | 2023-10-11 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신 |
| JP6961490B2 (ja) | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| BR112017017949A2 (pt) | 2015-05-15 | 2018-04-10 | Curevac Ag | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna |
| JP7048482B2 (ja) | 2015-08-03 | 2022-04-05 | アメリカ合衆国 | Ｂｒａｃｈｙｕｒｙ欠失変異体、Ｂｒａｃｈｙｕｒｙ欠失変異体をコードする非酵母ベクター、及びそれらの使用 |
| WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| MX391472B (es) | 2016-03-28 | 2025-03-21 | Ichor Medical Systems Inc | Metodo y aparato para suministro de agentes terapeuticos. |
| CN118063563A (zh) | 2016-04-06 | 2024-05-24 | 华盛顿大学 | 用于乙型肝炎病毒（hbv）的使用hbv核心抗原的治疗性疫苗 |
| WO2017180770A1 (en) | 2016-04-13 | 2017-10-19 | Synthetic Genomics, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| WO2018075235A1 (en) | 2016-10-17 | 2018-04-26 | Synthetic Genomics, Inc. | Recombinant virus replicon systems and uses thereof |
| US11845939B2 (en) | 2016-12-05 | 2023-12-19 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| EP3607968A4 (en) | 2017-06-05 | 2021-03-31 | Beacle Inc. | VIRAL-TYPE PARTICLES INTENDED FOR USE TO INDUCE AN IMMUNE RESPONSE AGAINST HBV |
| CN111542340B (zh) | 2017-11-16 | 2023-12-19 | 华盛顿大学 | 治疗性乙型肝炎病毒(hbv)疫苗 |
| SG11202005895QA (en) | 2017-12-19 | 2020-07-29 | Janssen Sciences Ireland Unlimited Co | Hepatitis b virus (hbv) vaccines and uses thereof |
| JP7494117B2 (ja) * | 2018-01-19 | 2024-06-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えレプリコン系を使用する免疫応答の誘導および増強 |
-
2017
- 2017-10-03 WO PCT/US2017/054928 patent/WO2018075235A1/en not_active Ceased
- 2017-10-03 EP EP17787724.8A patent/EP3526332B1/en active Active
- 2017-10-03 KR KR1020197013847A patent/KR102718353B1/ko active Active
- 2017-10-03 MX MX2019004499A patent/MX2019004499A/es unknown
- 2017-10-03 BR BR112019007433A patent/BR112019007433A2/pt unknown
- 2017-10-03 ES ES17787724T patent/ES2993107T3/es active Active
- 2017-10-03 AU AU2017347725A patent/AU2017347725B2/en active Active
- 2017-10-03 JP JP2019520535A patent/JP7382230B2/ja active Active
- 2017-10-03 CN CN201780075817.7A patent/CN110073002B/zh active Active
- 2017-10-03 US US15/723,658 patent/US11364310B2/en active Active
-
2022
- 2022-06-13 US US17/806,581 patent/US20230126773A1/en active Pending
-
2023
- 2023-06-21 JP JP2023101803A patent/JP2023134488A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023134488A5 (enExample) | ||
| JP2019530466A5 (enExample) | ||
| JP4790984B2 (ja) | アルファウイルスレプリコンベクター系 | |
| AU2008338803B2 (en) | Methods of generating alphavirus particles | |
| EP1141361B1 (en) | Compositions and methods for packaging of alphavirus vectors | |
| EP2305299B1 (en) | Chimeric alphavirus replicon particles | |
| US6692750B1 (en) | Alphavirus expression vector | |
| CA2410948C (en) | Method for the purification of alphavirus replicon particles | |
| US9255126B2 (en) | Chimeric alphavirus replicon particles | |
| AU2002303330A1 (en) | Chimeric alphavirus replicon particles | |
| JP2015527296A5 (enExample) | ||
| JP2005515755A5 (enExample) | ||
| CA2461380A1 (en) | Hepatitis c virus vaccine | |
| WO2008119827A1 (en) | Transreplicase constructs | |
| EP2331557B1 (en) | Alphavirus packaging cell lines | |
| Raffo et al. | Construction of tobacco mosaic virus subgenomic replicons that are replicated and spread systemically in tobacco plants | |
| EP1029069B1 (en) | Alphavirus vectors | |
| US6616929B1 (en) | Swine vesicular disease virus expression vectors | |
| HK1155984A (en) | Chimeric alphavirus replicon particles | |
| MXPA00004707A (es) | Vectores de alfa virus |